YOLFTbeta
BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd.

6733 · TWO · Healthcare / Biotechnology

20.40TWD-0.15 (-0.73%)

Price History

Full chart

Market Stats

Previous Close20.55
Open20.35
Day Range20.20 – 20.65
52-Week Range23.45 – 46.75
Volume98.52K
Market Cap3.37B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.54
Dividend Yield0.00%
Beta0.07
50-Day Avg25.90
200-Day Avg30.27

About

BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong, Chinese Mainland, and Malaysia. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Te-Li Chen M.D., Ph.D.
  • Employees0
  • HeadquartersNo.3-2, Park Street, Taipei, Taiwan, 115, Taiwan
  • Websitehttps://www.biogend.com

Leadership

  • Dr. Te-Li Chen M.D., Ph.D.Chairman & GM · b. 1969
  • Guifen ZhangSenior Manager
  • Shuwei ZhaoSenior Manager
  • Bozhi ZhangSenior Manager
  • Bowei LiSenior Manager

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue9.27M31.45M109.91M167.65M222.34M
Growth (%)-+239.26%+249.51%+52.53%+32.62%
Cost of Revenue6.21M8.67M20.29M37.14M62.18M
Gross Profit3.06M22.78M89.62M130.51M160.16M
Gross Margin33.00%72.44%81.54%77.85%72.03%
Operating Expense167.37M241.99M266.16M252.77M269.86M
Operating Income-164.31M-219.21M-176.54M-122.26M-109.70M
Operating Margin-1772.67%-697.11%-160.63%-72.93%-49.34%
EBITDA--160.62M-113.94M-76.85M-53.69M
EBITDA Margin--510.78%-103.67%-45.84%-24.15%
Net Income-138.49M-184.46M-156.32M-116.47M-84.61M
Net Income Margin-1494.07%-586.58%-142.23%-69.47%-38.05%
R&D113.27M166.27M171.00M128.72M124.45M
R&D as % of Total Revenue1222.07%528.73%155.58%76.78%55.97%
Interest Expense18.00K91.00K262.00K215.00K151.00K
Interest Expense % of Total Revenue0.19%0.29%0.24%0.13%0.07%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.02B821.82M1.05B912.70M815.38M
Total Liabilities80.42M90.56M93.71M66.19M57.74M
Total Equity887.54M702.86M940.96M817.67M742.09M
Cash136.32M163.64M330.51M219.02M217.90M

Cash Flow

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--136.80M-168.78M-138.72M-98.91M-63.66M
Capital Expenditure0673.00K18.18M25.71M650.00K1.86M
Free Cash Flow--137.47M-186.96M-164.44M-99.56M-65.52M
FCF to OCF-100.49%110.77%118.54%100.66%102.93%

Earnings

Report DateAug 9, 2021Nov 10, 2021Mar 2, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Feb 27, 2025Nov 10, 2025Feb 26, 2026
EPS Estimate-0.37-0.37-0.33-0.24-0.23-0.26-0.28-0.09-0.10
EPS Actual-0.38-0.39-0.26-0.09-0.28-0.25-0.32-0.05-0.18
Surprise-2.70%-5.41%21.21%62.50%-21.74%3.85%-14.29%44.44%-80.00%
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap3.37B
Enterprise Value2.56B
Trailing P/E0.00
Forward P/E0.00
Price / Sales14.25
Price / Book3.19
EPS-0.54
Book Value7.95
Revenue (TTM)236.58M
Gross Profit (TTM)167.18M
EBITDA-46.22M
Profit Margin-28.67%
Operating Margin-53.01%
Return on Equity-8.17%
Return on Assets-5.83%
Shares Outstanding134.32M
Shares Float77.47M
Beta0.07
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%